#Lung Cancer

Framingham, MAPosted by
FraminghamSOURCE

U.S. News & World Report Names MetroWest Medical High Performing Hospital for Common Adult Procedures & Conditions

FRAMINGHAM – MetroWest Medical Center is recognized as a High Performing Hospital for 2020-21 by U.S. News & World Report. MetroWest Medical Center earns “High Performing” ratings for its exceptional care of patients with chronic obstructive pulmonary disease (COPD), heart failure, kidney failure and lung cancer surgery. “High Performing” is the highest rating U.S. News awards for common adult procedures and conditions, recognizing care that is significantly better than the national average as measured by factors such as patient outcomes.
Picture for U.S. News & World Report Names MetroWest Medical High Performing Hospital for Common Adult Procedures & Conditions
TRENDING TOPICS
Cancerhealththoroughfare.com

How Lung Cancer Patients Can Get a Life Extension

Who doesn’t like the idea of living longer? Many of us would even want to live forever, but time is like a tyrant who doesn’t forgive anyone. Lung cancer is the most lethal type of cancer for both men and women from the US. The disease kills more people every year than prostate, breast, and colon cancer combined.
Oklahoma Statenews9.com

Oklahoma Woman Receives Support From Family, Friends In Her Fight Against Cancer

Back in February Susan Esco contracted COVID-19, but she continued to feel bad. So, her doctors ordered X-rays and they discovered she had stage three lung cancer. Doctors recommended she go to MD Anderson. So as Susan and her husband packed the dogs in preparation of moving to Houston for six weeks, about 50 of her friends had a prayer meeting with her in her home.
Diseases & TreatmentsMedicalXpress

Smoking cessation after NSCLC diagnosis cuts mortality risk

(HealthDay)—For patients with non-small cell lung cancer (NSCLC), smoking cessation after diagnosis is associated with a reduced risk for all-cause mortality, cancer-specific mortality, and disease progression, according to a study published online July 27 in the Annals of Internal Medicine. Mahdi Sheikh, M.D., Ph.D., from the International Agency for Research...
Sarasota, FLsarasotamagazine.com

SMH Earns Multiple Spots on U.S. News 'Best Hospitals' List

Sarasota Memorial Hospital earned top marks in U.S. News' 2021-2022 “Best Hospitals” list, released this week. This year’s rankings place SMH among the 50 “Best Hospitals” in America for specialized rehabilitation for people recovering from serious injuries and debilitating diseases. SMH also achieved “high performer” ratings in 15 procedures and conditions common among Medicare patients, including abdominal aortic aneurysm repair (AAA), aortic valve surgery, back surgery (spinal fusion), congestive obstructive pulmonary disease (COPD), colon cancer surgery, diabetes, heart attack, heart bypass surgery, heart failure, hip replacement, kidney failure, knee replacement, lung cancer surgery, stroke and transcatheter aortic valve replacement (TAVR).
CancerNature.com

Downregulation of TMEM220 promotes tumor progression in Hepatocellular Carcinoma

During the process of long-term carcinogenesis, cells accumulate many mutations. Deregulated genes expression causes profound changes in cell proliferation, which is one of the hallmarks of HCC. A comprehensive understanding of these changes will contribute to the molecular mechanism of HCC progression. Through clinical sample analysis, we found that TMEM220 is downregulated in tumor and lower levels of TMEM220 is associated with poor prognosis in HCC patients. Through overexpressing TMEM220 in HCC cell lines, we found that the proliferation of cancer cells was significantly slowed down and metastasis was significantly reduced. For further study of its molecular mechanism, we performed a reverse-phase protein array (RPPA). The results suggest that phenotypic changes caused by TMEM220 in HCC cells might be associated with FOXO and PI3K-Akt pathways. Mechanism studies showed that overexpression of TMEM220 could regulate β-catenin and FOXO3 transcriptional activity by altering their subcellular localization, affecting the expression of downstream gene p21 and SNAIL, and ultimately reducing the progression of HCC. Altogether, our study proposes a working model in which upregulation of TMEM220 expression alters the genes expression involved in cell proliferation, thereby inhibiting HCC progression, which suggests that TMEM220 might serve as a clinical biomarker.
CancerNature.com

Changes in expression of PD-L1 on peripheral T cells in patients with melanoma and lung cancer treated with PD-1 inhibitors

Advances in cancer immunology have increased the use of immune checkpoint inhibitors in clinical practice, however not all patients respond, and treatment can have severe side-effects. Blood-based immunological biomarkers are an attractive method for predicting which patients will respond to therapy, however, reliable biomarkers for immune checkpoint blockade are lacking. This study aimed to identify patients before or early in treatment who would best respond to PD-1 inhibitors. We hypothesised that higher baseline PD-L1 and/or PD-1 on peripheral blood T cells could predict radiological response to PD-1 inhibitors. This pilot prospective cohort study assessed 26 patients with melanoma or non-small cell lung cancer, treated with pembrolizumab, nivolumab, or nivolumab/ipilimumab combined. Response was assessed by RECIST 1.1. Peripheral blood lymphocytes collected at baseline, after one cycle, 10 weeks and at discontinuation of therapy were analysed by flow cytometry. Patients with a higher proportion of PD-L1+ T cells at baseline had improved objective response to PD-1 inhibitor therapy, and patients with a lower proportion of regulatory T cells at baseline experienced more immune-related adverse events. These findings may prove useful to assist in clinical decision making. Further studies with larger cohorts are required to validate these findings.
Financial ReportsPosted by
Reuters

Bristol Myers sees return to growth for Opdivo, tops estimates

(Reuters) - Bristol Myers Squibb Co reported second quarter earnings that topped Wall Street estimates, as sales of flagship cancer treatment Opdivo returned to growth after missing estimates in the previous quarter. Excluding one-time items, Bristol Myers reported earnings of $4.3 billion, or $1.93 per share, beating analyst estimates of...
CancerPosted by
105.7 The Hawk

Early detection saves lives: Get a cancer screening

Cancer screening rates dropped almost 85% during the height of the COVID-19 pandemic, leading to later-stage diagnoses, complicated treatments and greater risk of death. Now, New Jersey oncologists are urging residents not to further delay such screenings. They hope to do this with a new campaign called "Time to Screen,"...
CancerNature.com

miR-526b-3p inhibits lung cancer cisplatin-resistance and metastasis by inhibiting STAT3-promoted PD-L1

Chemotherapy remains the primary treatment of advanced solid cancer, including lung cancer. However, as first-line treatment, cisplatin-based therapy is restricted by the frequent development of drug resistance. Increasing data showed that the programmed cell death protein ligand 1 (PD-L1) plays a vital role in regulating cisplatin resistance. However, the underlying mechanisms are not fully understood. We found that miR-526b-3p expression declined while PD-L1 was elevated in cisplatin-resistant lung cancer compared to that in cisplatin-sensitive lung cancer by analyzing clinical samples. Significantly, miR-526b-3p was associated with response to cisplatin negatively. We further demonstrated that miR-526b-3p reversed cisplatin resistance, suppressed metastasis, and activated CD8+ T cells in a STAT3/PD-L1-dependent manner. Thus, our findings extended the knowledge of PD-L1-mediated cisplatin resistance of lung cancer. In addition, the introduction of miR-526b-3p provided a new clue to improve the anti-tumor effects of the combination of immunotherapy and chemotherapy.
YOU MAY ALSO LIKE